PLAT and Obesity: Given that obesity is a significant risk factor for stroke, silymarin could be a promising adjunct therapy for improving post-stroke outcomes, particularly in patients not eligible for recanalization therapies like tissue plasminogen activator due to the short therapeutic window, leaving patients with limited treatment options (Kang et al., 2021).